［Abstract］　T-follicular helper cell lymphoma(T-FHCL) is a type of peripheral T-cell lymphoma. The understanding of T-FHCL has been evolving over the course of several decades, and it was classified into three subcategories by the World Health Organization in 2017. Because T-FHCL often has misleading histopathological manifestations and incompletely clarified pathogenesis, its diagnosis is challenging and usually requires a series of multifaceted evaluations, especially for angioimmunoblastic T-cell lymphoma(the most common of the three subcategories). Along with recent advances in the field of molecular biology, the genomic landscape of T-FHCL has been unraveled, and the mechanism underlying its lymphomagenesis, especially the development of its unique microenvironment, is now better understood. In this commentary, we not only summarize the pathological features, the updated diagnostic criteria, and classification of T-FHCL, but also discuss the latest advances in the molecular study of T-FHCL and its application in diagnosis and disease classification.]]> 2021/9/30 20:36:22 2true ［Abstract］　Immunotherapy has joined surgery, radiation, and traditional chemotherapy to become the fourth pillar in cancer treatment. The concept of using one′s own immune system to treat cancer has inspired numerous therapies. The class of immunotherapies that has proven most effective is the checkpoint inhibitors(CPIs), which work by blocking immunosuppressive mechanisms. Prime examples of CPIs in clinical use are based on Nobel Prize winning discovery of PD-1/L1 and CTLA-4. The clinical responses to immunotherapies vary, and this is in part due to differences in the tumor microenvironment. Tumors that are poorly infiltrated by lymphocytes are immunologically inert and are referred to as “cold tumors” and tend to respond poorly to CPIs. We review current immunotherapies and examples of efforts to increase lymphocyte infiltration in cold tumors to improve outcomes of CPIs.]]> 2021/9/30 20:36:22 1true